Literature DB >> 8204403

Radioimmunoscintigraphy of CEA/CA 19-9 producing tumors with I-131 labeled monoclonal antibodies.

A S Arbab1, K Koizumi, G Uchiyama, T Arai, H Eguchi, Y Matsumoto, K Suda.   

Abstract

A total of 7 (4 males and 3 females) patients were included in this retrospective study to determine the sensitivity of radioimmunoscintigraphy with I-131 labeled anti CEA/CA 19-9 monoclonal antibodies. Out of 7 patients 2 had ascending colon cancer, one had sigmoid colon cancer, one had rectal cancer and one had adenocarcinoma in the CBD and the remaining two had metastatic tumor (one in the lungs and the other in the liver). Whole body as well as spot images showed a 72% (5/7) positive scan. But post operative specimen counts and imaging showed a high tumor to non-tumor ratio and a good tumor to non-tumor contrast of activity of I-131 labeled monoclonal antibody. We did not find any relation between CEA/CA 19-9 levels and scan findings. A case of liver metastasis was also detected by this radioimmunoscintigraphy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204403     DOI: 10.1007/bf03164981

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  13 in total

Review 1.  Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials.

Authors:  S M Larson
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

Review 2.  CEA-related antigens: molecular biology and clinical significance.

Authors:  J E Shively; J D Beatty
Journal:  Crit Rev Oncol Hematol       Date:  1985       Impact factor: 6.312

Review 3.  Imaging of colorectal carcinoma with radiolabeled antibodies.

Authors:  D M Goldenberg; H Goldenberg; R M Sharkey; R E Lee; E Higgenbotham-Ford; J A Horowitz; T C Hall; C M Pinsky; H J Hansen
Journal:  Semin Nucl Med       Date:  1989-10       Impact factor: 4.446

Review 4.  Labeling of monoclonal antibodies with radionuclides.

Authors:  K K Bhargava; S A Acharya
Journal:  Semin Nucl Med       Date:  1989-07       Impact factor: 4.446

5.  Alterations in an indium-111 Fab' under conditions of utilization.

Authors:  S E Halpern; J P Tarburton; E Sudora; P Hagan
Journal:  Eur J Nucl Med       Date:  1992

6.  Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody.

Authors:  J A Carrasquillo; P Sugarbaker; D Colcher; J C Reynolds; J Esteban; G Bryant; A M Keenan; P Perentesis; K Yokoyama; D E Simpson
Journal:  J Nucl Med       Date:  1988-06       Impact factor: 10.057

7.  Radioimmunodetection of occult carcinoembryonic antigen-producing cancer.

Authors:  M K Haseman; D W Brown; C A Keeling; N L Reed
Journal:  J Nucl Med       Date:  1992-10       Impact factor: 10.057

8.  Radiation dosimetry for indium-111-labeled anti-CEA-F(ab')2 fragments evaluated from tissue distribution in rats.

Authors:  B A Jönsson; S E Strand; L Andersson
Journal:  J Nucl Med       Date:  1992-09       Impact factor: 10.057

9.  Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmapheresis.

Authors:  A M Zimmer; S T Rosen; S M Spies; R Goldman-Leikin; J M Kazikiewicz; E A Silverstein; E H Kaplan
Journal:  J Nucl Med       Date:  1988-02       Impact factor: 10.057

10.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.